A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer

被引:12
作者
Pathak, Pranav [1 ]
Pajai, Sandhya [1 ]
Kesharwani, Himanshi [1 ]
机构
[1] Datta Meghe Inst Med Sci, Jawaharlal Nehru Med Coll, Obstet & Gynaecol, Wardha, India
关键词
womens health; cervical cancer prevention; cancer cervical; cervical cancer vaccines; gardasil; immunoprevention; vaccination; human papillomavirus; HUMAN-PAPILLOMAVIRUS VACCINE; INDIA; WOMEN;
D O I
10.7759/cureus.28710
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The main risk factor for invasive cervical carcinoma is persistent infection by the high-risk human papillomavirus (HPV). HPV is the most prevalent sexually transmitted infection (STI) and has been linked to 15 different cancers. Cervical cancer is one of the most frequent cancers among women, particularly in resource-limited countries. Cervical cancer is an HPV disease with the highest worldwide burden in resource-limited nations. With improved medical care and nationwide screening programmes, the mortality rate from cervical cancer has decreased in the past 40 years. Many developing nations have been shown to have inadequate knowledge and health-seeking practices, making proper awareness and immunisation programmes necessary. The best strategy to reduce the incidence of cervical cancer is through the administration of HPV vaccines along with routine cervical screening. The HPV vaccine is crucial for public health. Vaccinations against all HPV subtypes, namely, bivalent, quadrivalent, and nonavalent, are available. Financial issues are the main barrier to HPV vaccination. The framework for behavioural and social drivers of vaccination, which includes practical concerns, motivation, social processes, thoughts, and feelings, is widely used to uncover important aspects linked with HPV vaccination. The burden of cervical cancer due to HPV and the advantages of HPV vaccination are summarised in this review article.
引用
收藏
页数:7
相关论文
共 36 条
  • [1] Prophylactic HPV vaccination for women over 18 years of age
    Adams, M.
    Jasani, B.
    Fiander, A.
    [J]. VACCINE, 2009, 27 (25-26) : 3391 - 3394
  • [2] [Anonymous], 2020, Cervical Cancer Elimination Initiative, World Health Organization
  • [3] [Anonymous], 2021, Cervical Cancer India 2021 country profile
  • [4] [Anonymous], 2022, CONFIDENCE DEMAND
  • [5] [Anonymous], 2020, CERVIX UTERI
  • [6] [Anonymous], 2021, HIGHL M STRAT ADV GR
  • [7] [Anonymous], 2020, GLOBAL STRATEGY ACCE
  • [8] Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
    Bahmanyar, Edith Roset
    Paavonen, Jorma
    Naud, Paulo
    Salmeron, Jorge
    Chow, Song-Nan
    Apter, Dan
    Kitchener, Henry
    Castellsague, Xavier
    Teixeira, Julio C.
    Skinner, S. Rachel
    Jaisamrarn, Unnop
    Limson, Genara A.
    Garland, Suzanne M.
    Szarewski, Anne
    Romanowski, Barbara
    Aoki, Fred
    Schwarz, Tino F.
    Poppe, Willy A. J.
    De Carvalho, Newton S.
    Harper, Diane M.
    Bosch, F. Xavier
    Raillard, Alice
    Descamps, Dominique
    Struyf, Frank
    Lehtinen, Matti
    Dubin, Gary
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 440 - 450
  • [9] Acceptability of human papillomavirus vaccine among the urban, affluent and educated parents of young girls residing in Kolkata, Eastern India
    Basu, Partha
    Mittal, Srabani
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2011, 37 (05) : 393 - 401
  • [10] Chatterjee Sharmila, 2016, Asian Pac J Cancer Prev, V17, P3663